These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20403471)

  • 1. Effect of Angiotensin-converting enzyme inhibition on one-year mortality and frequency of repeat acute myocardial infarction in patients with acute myocardial infarction.
    Milonas C; Jernberg T; Lindbäck J; Agewall S; Wallentin L; Stenestrand U;
    Am J Cardiol; 2010 May; 105(9):1229-34. PubMed ID: 20403471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of renin-angiotensin system inhibitors on long-term survival in patients treated with beta blockers and antiplatelet agents after acute myocardial infarction (from the MONICA/KORA Myocardial Infarction Registry).
    Amann U; Kirchberger I; Heier M; Zirngibl A; von Scheidt W; Kuch B; Peters A; Meisinger C
    Am J Cardiol; 2014 Aug; 114(3):329-35. PubMed ID: 24927969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [ACE inhibitors and angiotensin II receptor antagonists in acute coronary syndrome].
    Milicić D
    Acta Med Croatica; 2004; 58(2):129-34. PubMed ID: 15208798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of combined beta-blocker and angiotensin-converting enzyme inhibitor treatment on 1-year survival after acute myocardial infarction: findings of the PRIAMHO-II registry].
    Arós F; Loma-Osorio A; Vila J; López-Bescós L; Cuñat J; Rodríguez E; San José JM; Heras M; Marrugat J;
    Rev Esp Cardiol; 2006 Apr; 59(4):313-20. PubMed ID: 16709383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM; Lokhnygina Y; Velazquez EJ; McMurray JJ; Leimberger JD; Lewis EF; Diaz R; Murin J; Pfeffer MA
    Am J Cardiol; 2009 Jul; 104(2):151-7. PubMed ID: 19576338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is angiotensin-converting enzyme inhibitor useful in a Japanese population for secondary prevention after acute myocardial infarction? A final report of the Japanese Acute Myocardial Infarction Prospective (JAMP) study.
    Ueshima K; Fukami K; Hiramori K; Hosoda S; Kishida H; Kato K; Fujita T; Tsutani K; Sakuma A;
    Am Heart J; 2004 Aug; 148(2):e8. PubMed ID: 15309011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
    Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
    Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
    Magrini G; Nicolosi GL; Chiariello M; Ferrari R; Remme P; Tavazzi L
    Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of implementing routine early invasive strategy on one-year mortality in patients with acute myocardial infarction.
    Aune E; Endresen K; Fox KA; Steen-Hansen JE; Roislien J; Hjelmesaeth J; Otterstad JE
    Am J Cardiol; 2010 Jan; 105(1):36-42. PubMed ID: 20102887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
    Suşan M; Petrescu L; Riviş AI; Suşan RM; Burghină D; Dan R; Cozma D; Drăgulescu SI
    Rom J Intern Med; 2005; 43(3-4):187-98. PubMed ID: 16812979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Too little aspirin for secondary prevention after acute myocardial infarction in patients at high risk for cardiovascular events: Results from the MITRA study.
    Frilling B; Schiele R; Gitt AK; Zahn R; Schneider S; Glunz HG; Gieseler U; Jagodzinski E; Senges J;
    Am Heart J; 2004 Aug; 148(2):306-11. PubMed ID: 15309001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
    Danchin N; Cucherat M; Thuillez C; Durand E; Kadri Z; Steg PG
    Arch Intern Med; 2006 Apr; 166(7):787-96. PubMed ID: 16606817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suboptimal use of evidence-based medical therapy in patients with acute myocardial infarction from the Korea Acute Myocardial Infarction Registry: prescription rate, predictors, and prognostic value.
    Lee JH; Yang DH; Park HS; Cho Y; Jeong MH; Kim YJ; Kim KS; Hur SH; Seong IW; Hong TJ; Cho MC; Kim CJ; Jun JE; Park WH; Chae SC;
    Am Heart J; 2010 Jun; 159(6):1012-9. PubMed ID: 20569714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis.
    Setoguchi S; Glynn RJ; Avorn J; Mittleman MA; Levin R; Winkelmayer WC
    J Am Coll Cardiol; 2008 Apr; 51(13):1247-54. PubMed ID: 18371553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators.
    Ambrosioni E; Borghi C; Magnani B
    N Engl J Med; 1995 Jan; 332(2):80-5. PubMed ID: 7990904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study.
    Ferrari R;
    Arch Intern Med; 2006 Mar; 166(6):659-66. PubMed ID: 16567606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends and outcomes associated with angiotensin-converting enzyme inhibitors.
    Doubeni C; Bigelow C; Lessard D; Spencer F; Yarzebski J; Gore J; Gurwitz J; Goldberg R
    Am J Med; 2006 Jul; 119(7):616.e9-16. PubMed ID: 16828635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
    Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R
    J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Management of acute myocardial infarction in the experience of a community hospital. A prospective study].
    Tincani E; Mazzoli V; Bondi M
    Minerva Cardioangiol; 1997; 45(7-8):335-47. PubMed ID: 9463169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction.
    Evans M; Carrero JJ; Szummer K; Åkerblom A; Edfors R; Spaak J; Jacobson SH; Andell P; Lindhagen L; Jernberg T
    J Am Coll Cardiol; 2016 Apr; 67(14):1687-97. PubMed ID: 27056774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.